Cargando…
Modulation of HIV-1 immunity by adjuvants
PURPOSE OF REVIEW: To summarize the role of adjuvants in eliciting desirable antibody responses against HIV-1 with particular emphasis on both historical context and recent developments. RECENT FINDINGS: Increased understanding of the role of pattern recognition receptors such as Toll-like receptors...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984023/ https://www.ncbi.nlm.nih.gov/pubmed/24670321 http://dx.doi.org/10.1097/COH.0000000000000052 |
_version_ | 1782311385396412416 |
---|---|
author | Moody, M. Anthony |
author_facet | Moody, M. Anthony |
author_sort | Moody, M. Anthony |
collection | PubMed |
description | PURPOSE OF REVIEW: To summarize the role of adjuvants in eliciting desirable antibody responses against HIV-1 with particular emphasis on both historical context and recent developments. RECENT FINDINGS: Increased understanding of the role of pattern recognition receptors such as Toll-like receptors in recruiting and directing the immune system has increased the variety of adjuvant formulations being tested in animal models and humans. Across all vaccine platforms, adjuvant formulations have been shown to enhance desirable immune responses such as higher antibody titers and increased functional activity. Although no vaccine formulation has yet succeeded in eliciting broad neutralizing antibodies against HIV-1, the ability of adjuvants to direct the immune response to immunogens suggests they will be critically important in any successful HIV-1 vaccine. SUMMARY: The parallel development of adjuvants along with better HIV-1 immunogens will be needed for a successful AIDS vaccine. Additional comparative testing will be required to determine the optimal adjuvant and immunogen regimen that can elicit antibody responses capable of blocking HIV-1 transmission. |
format | Online Article Text |
id | pubmed-3984023 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-39840232014-04-14 Modulation of HIV-1 immunity by adjuvants Moody, M. Anthony Curr Opin HIV AIDS SPECTRUM OF HIV ANTIBODIES IN VACCINE AND DISEASE: Edited by Georgia D. Tomaras and David C. Montefiori PURPOSE OF REVIEW: To summarize the role of adjuvants in eliciting desirable antibody responses against HIV-1 with particular emphasis on both historical context and recent developments. RECENT FINDINGS: Increased understanding of the role of pattern recognition receptors such as Toll-like receptors in recruiting and directing the immune system has increased the variety of adjuvant formulations being tested in animal models and humans. Across all vaccine platforms, adjuvant formulations have been shown to enhance desirable immune responses such as higher antibody titers and increased functional activity. Although no vaccine formulation has yet succeeded in eliciting broad neutralizing antibodies against HIV-1, the ability of adjuvants to direct the immune response to immunogens suggests they will be critically important in any successful HIV-1 vaccine. SUMMARY: The parallel development of adjuvants along with better HIV-1 immunogens will be needed for a successful AIDS vaccine. Additional comparative testing will be required to determine the optimal adjuvant and immunogen regimen that can elicit antibody responses capable of blocking HIV-1 transmission. Lippincott Williams & Wilkins 2014-05 2014-04-10 /pmc/articles/PMC3984023/ /pubmed/24670321 http://dx.doi.org/10.1097/COH.0000000000000052 Text en © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. |
spellingShingle | SPECTRUM OF HIV ANTIBODIES IN VACCINE AND DISEASE: Edited by Georgia D. Tomaras and David C. Montefiori Moody, M. Anthony Modulation of HIV-1 immunity by adjuvants |
title | Modulation of HIV-1 immunity by adjuvants |
title_full | Modulation of HIV-1 immunity by adjuvants |
title_fullStr | Modulation of HIV-1 immunity by adjuvants |
title_full_unstemmed | Modulation of HIV-1 immunity by adjuvants |
title_short | Modulation of HIV-1 immunity by adjuvants |
title_sort | modulation of hiv-1 immunity by adjuvants |
topic | SPECTRUM OF HIV ANTIBODIES IN VACCINE AND DISEASE: Edited by Georgia D. Tomaras and David C. Montefiori |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984023/ https://www.ncbi.nlm.nih.gov/pubmed/24670321 http://dx.doi.org/10.1097/COH.0000000000000052 |
work_keys_str_mv | AT moodymanthony modulationofhiv1immunitybyadjuvants |